New First-Line Treatment Option for Metastatic Kidney Cancer, According to Results of Phase 3 Study

San Francisco, CA (UroToday.com) — The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020.¹